has acted as a consultant for, received grant or research support from, is a shareholder in, and a holds a patent from Centocor JNJ
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Kenyas amaranth and finger millet selected for global conservation, promotion funding
Vendors are developing solutions in the GLP-1 space that involve weight management, prescribing, diabetes/hypertension management, pre-diabetes and more
Can GLP1 receptor agonists be prescribed to treat depression
More recent studies expanded this work
